BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 10, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BSD-2000 Hyperthermia System: Phase III data

Data from an international Phase III trial in 341 patients with localized, high-risk STS showed that the BSD-2000 Hyperthermia System plus neoadjuvant chemotherapy with etoposide, ifosfamide and doxorubicin significantly reduced local tumor progression at 2 years vs. chemotherapy alone (19% vs. 30%, p=0.003). BSD-2000 plus chemotherapy also led to significantly greater...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >